CA2594255A1 - Novel pyridine compounds - Google Patents
Novel pyridine compounds Download PDFInfo
- Publication number
- CA2594255A1 CA2594255A1 CA002594255A CA2594255A CA2594255A1 CA 2594255 A1 CA2594255 A1 CA 2594255A1 CA 002594255 A CA002594255 A CA 002594255A CA 2594255 A CA2594255 A CA 2594255A CA 2594255 A1 CA2594255 A1 CA 2594255A1
- Authority
- CA
- Canada
- Prior art keywords
- heterocyclyl
- amino
- aryl
- cycloalkyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003222 pyridines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 40
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 406
- 125000003118 aryl group Chemical group 0.000 claims description 403
- -1 arylC(O) Chemical group 0.000 claims description 367
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 236
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 145
- 229910052736 halogen Inorganic materials 0.000 claims description 132
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 127
- 150000002367 halogens Chemical class 0.000 claims description 126
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 124
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 117
- 229910052801 chlorine Inorganic materials 0.000 claims description 117
- 229910052794 bromium Inorganic materials 0.000 claims description 116
- 229910052731 fluorine Inorganic materials 0.000 claims description 116
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 112
- 229910052760 oxygen Inorganic materials 0.000 claims description 112
- 239000001301 oxygen Substances 0.000 claims description 112
- 125000004429 atom Chemical group 0.000 claims description 109
- 229910052740 iodine Inorganic materials 0.000 claims description 109
- 229910052757 nitrogen Inorganic materials 0.000 claims description 109
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 108
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 106
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 83
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 79
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 77
- 235000001968 nicotinic acid Nutrition 0.000 claims description 76
- 239000011664 nicotinic acid Substances 0.000 claims description 76
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 70
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 70
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 67
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 62
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 53
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 50
- 125000004122 cyclic group Chemical group 0.000 claims description 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 46
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 38
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 37
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 37
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 10
- 239000005864 Sulphur Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- UBLUZXPVNMESOL-UHFFFAOYSA-N ethyl 6-[3-(benzenesulfonylcarbamoylamino)azetidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(NC(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 UBLUZXPVNMESOL-UHFFFAOYSA-N 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 150000003868 ammonium compounds Chemical class 0.000 claims description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- IUFLJCZIMLKGQN-UHFFFAOYSA-N 3-[1-(benzenesulfonylcarbamoyl)-4-[3-cyano-5-ethoxycarbonyl-6-(trifluoromethyl)pyridin-2-yl]piperazin-2-yl]propanoic acid Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 IUFLJCZIMLKGQN-UHFFFAOYSA-N 0.000 claims description 4
- VGMHGUWPHMZGNB-UHFFFAOYSA-N 4-(5-butanoyl-3-chloropyridin-2-yl)-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound ClC1=CC(C(=O)CCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VGMHGUWPHMZGNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 102220535958 Dynein axonemal intermediate chain 4_R17S_mutation Human genes 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- RBEPZLOCUMMCFC-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoylamino)piperidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(NC(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 RBEPZLOCUMMCFC-UHFFFAOYSA-N 0.000 claims description 4
- MWNQODBRDGOPEN-UHFFFAOYSA-N ethyl 6-[4-[(2-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)CC1 MWNQODBRDGOPEN-UHFFFAOYSA-N 0.000 claims description 4
- QPTUDBWQWSMCEA-UHFFFAOYSA-N ethyl 6-[4-[(4-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 QPTUDBWQWSMCEA-UHFFFAOYSA-N 0.000 claims description 4
- UACQSHPMVFGLEW-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-ethyl-4,5-dihydro-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(CC)CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 UACQSHPMVFGLEW-UHFFFAOYSA-N 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 102200078752 rs201827340 Human genes 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- TUXQEPDPBKJWMS-UHFFFAOYSA-N 2,2-dimethylpropyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C1=C(C(=O)OCC(C)(C)C)C(C)=NC(N2CC(C2)NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)=C1C#N TUXQEPDPBKJWMS-UHFFFAOYSA-N 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- YPFCJBJMMACVBE-UHFFFAOYSA-N 3-[1-(benzenesulfonylcarbamoyl)-4-(3-chloro-5-ethoxycarbonylpyridin-2-yl)piperazin-2-yl]propanoic acid Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 YPFCJBJMMACVBE-UHFFFAOYSA-N 0.000 claims description 3
- ICKIAJXQACGDGC-UHFFFAOYSA-N 3-[1-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-4-[3-cyano-5-[ethoxy(hydroxy)methyl]-6-(trifluoromethyl)pyridin-2-yl]piperazin-2-yl]propanoic acid Chemical compound N1=C(C(F)(F)F)C(C(O)OCC)=CC(C#N)=C1N1CC(CCC(O)=O)N(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 ICKIAJXQACGDGC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- MMCYXMUZXDBPKB-UHFFFAOYSA-N 3-methylbutyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCC(C)C)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 MMCYXMUZXDBPKB-UHFFFAOYSA-N 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- QDGXKCGRYRQCFY-UHFFFAOYSA-N 4-[3-chloro-5-(2-ethyltetrazol-5-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound CCN1N=NC(C=2C=C(Cl)C(N3CCN(CC3)C(=O)NS(=O)(=O)C=3SC(Cl)=CC=3)=NC=2)=N1 QDGXKCGRYRQCFY-UHFFFAOYSA-N 0.000 claims description 3
- MXUMUFQZUKAXKE-UHFFFAOYSA-N butyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 MXUMUFQZUKAXKE-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- JBKZHGWLYHHCRD-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(4-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 JBKZHGWLYHHCRD-UHFFFAOYSA-N 0.000 claims description 3
- PSJMJDNZFUDWHS-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(4-methylphenyl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)CC1 PSJMJDNZFUDWHS-UHFFFAOYSA-N 0.000 claims description 3
- KRICGQWFOCXJGJ-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(CCC(=O)OC(C)(C)C)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 KRICGQWFOCXJGJ-UHFFFAOYSA-N 0.000 claims description 3
- QRBKIMPLBWIGHP-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperidin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 QRBKIMPLBWIGHP-UHFFFAOYSA-N 0.000 claims description 3
- UIFRIEXMOTVTFS-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(=O)OC(C)(C)C)N(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 UIFRIEXMOTVTFS-UHFFFAOYSA-N 0.000 claims description 3
- PJSGCRCJPIGURW-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 PJSGCRCJPIGURW-UHFFFAOYSA-N 0.000 claims description 3
- VHZYXGNZMRAFNP-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VHZYXGNZMRAFNP-UHFFFAOYSA-N 0.000 claims description 3
- CFTMMJHRAWMXEM-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-ethylpyridine-3-carboxylate Chemical compound N1=C(CC)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CFTMMJHRAWMXEM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- XXFVNYOVKCSHGL-UHFFFAOYSA-N propan-2-yl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OC(C)C)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XXFVNYOVKCSHGL-UHFFFAOYSA-N 0.000 claims description 3
- HNMVRGMXVDIVNB-UHFFFAOYSA-N 1-[3-acetamido-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1NC(C)=O)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 HNMVRGMXVDIVNB-UHFFFAOYSA-N 0.000 claims description 2
- CVEAGYHCXXSRGU-UHFFFAOYSA-N 1-[3-amino-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1N)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CVEAGYHCXXSRGU-UHFFFAOYSA-N 0.000 claims description 2
- VHFMIBIYBOTTII-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-(hydroxymethyl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)CO)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VHFMIBIYBOTTII-UHFFFAOYSA-N 0.000 claims description 2
- XBPNTKUWKGRTFW-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-methoxypyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)OC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XBPNTKUWKGRTFW-UHFFFAOYSA-N 0.000 claims description 2
- KBYCNAMHIQHNIC-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-methylsulfinylpyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)S(C)=O)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 KBYCNAMHIQHNIC-UHFFFAOYSA-N 0.000 claims description 2
- MXXJAGIMRLDJFK-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-6-(methylamino)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(Cl)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1NC MXXJAGIMRLDJFK-UHFFFAOYSA-N 0.000 claims description 2
- OTNVITBUUXZTQF-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-6-methoxypyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(Cl)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1OC OTNVITBUUXZTQF-UHFFFAOYSA-N 0.000 claims description 2
- LLNLUPUKRRVHGT-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylazetidine-3-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 LLNLUPUKRRVHGT-UHFFFAOYSA-N 0.000 claims description 2
- QKKYTKNIBWEUKG-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 QKKYTKNIBWEUKG-UHFFFAOYSA-N 0.000 claims description 2
- JOFCRTUJZSGZJB-UHFFFAOYSA-N 1-[5-(5-butyl-1,3-oxazol-2-yl)-3-chloropyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CCCC)=CN=C1C(C=C1Cl)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 JOFCRTUJZSGZJB-UHFFFAOYSA-N 0.000 claims description 2
- ZJLCTLTYSGSDDL-UHFFFAOYSA-N 1-[6-amino-3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(Cl)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1N ZJLCTLTYSGSDDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- VZAZKZSGKCDENO-UHFFFAOYSA-N 4-[3-chloro-5-(3-methyl-1,2-oxazol-5-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1N=C(C)C=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 VZAZKZSGKCDENO-UHFFFAOYSA-N 0.000 claims description 2
- UQGABJOTOYVCCV-UHFFFAOYSA-N 4-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 UQGABJOTOYVCCV-UHFFFAOYSA-N 0.000 claims description 2
- JZUVWUCVDGUZFC-UHFFFAOYSA-N 4-[3-chloro-5-(5-methyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 JZUVWUCVDGUZFC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- PARBGNWIFVZWAN-UHFFFAOYSA-N ethyl 4-amino-5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=C(N)C(C(=O)OCC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 PARBGNWIFVZWAN-UHFFFAOYSA-N 0.000 claims description 2
- BYJMWFVRKNECFT-UHFFFAOYSA-N ethyl 5-chloro-6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]pyrrolidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 BYJMWFVRKNECFT-UHFFFAOYSA-N 0.000 claims description 2
- ICIHBWFXUFQYTQ-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(2-chlorophenyl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)CC1 ICIHBWFXUFQYTQ-UHFFFAOYSA-N 0.000 claims description 2
- INWVOWWBLBBQBZ-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(2-methylphenyl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)CC1 INWVOWWBLBBQBZ-UHFFFAOYSA-N 0.000 claims description 2
- RQEHXCUFAJNTHP-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RQEHXCUFAJNTHP-UHFFFAOYSA-N 0.000 claims description 2
- DVMNZAAUBXQFFJ-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-2,4-dimethylpyridine-3-carboxylate Chemical compound ClC1=C(C)C(C(=O)OCC)=C(C)N=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 DVMNZAAUBXQFFJ-UHFFFAOYSA-N 0.000 claims description 2
- ATMSUCFFJIUPRV-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 ATMSUCFFJIUPRV-UHFFFAOYSA-N 0.000 claims description 2
- BMDDDCDAEYAZLS-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(5-methyl-1,2-oxazol-4-yl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(ON=C2)C)C1 BMDDDCDAEYAZLS-UHFFFAOYSA-N 0.000 claims description 2
- WFIHEMPOQDQXCS-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[3-(trifluoromethyl)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)C(F)(F)F)C1 WFIHEMPOQDQXCS-UHFFFAOYSA-N 0.000 claims description 2
- MUBTYELGPLBCFH-UHFFFAOYSA-N ethyl 5-cyano-6-[3-(2,3-dihydro-1-benzofuran-5-ylsulfonylcarbamoyl)azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C3CCOC3=CC=2)C1 MUBTYELGPLBCFH-UHFFFAOYSA-N 0.000 claims description 2
- HZSOYWILVRWZFN-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,4-dichlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC(Cl)=CC=2)Cl)C1 HZSOYWILVRWZFN-UHFFFAOYSA-N 0.000 claims description 2
- IDRBWZGCZZKPHJ-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dimethylfuran-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(OC(C)=C2)C)C1 IDRBWZGCZZKPHJ-UHFFFAOYSA-N 0.000 claims description 2
- JYYCHOJJACQKFL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4,5-dichlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=C(Cl)C=2)C1 JYYCHOJJACQKFL-UHFFFAOYSA-N 0.000 claims description 2
- VOVYHXLIGTYROG-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4-cyanophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(=CC=2)C#N)C1 VOVYHXLIGTYROG-UHFFFAOYSA-N 0.000 claims description 2
- FGWISMSMQQPUJZ-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4-methoxyphenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(OC)=CC=2)C1 FGWISMSMQQPUJZ-UHFFFAOYSA-N 0.000 claims description 2
- KIPUPHQPSGWIFX-UHFFFAOYSA-N ethyl 5-cyano-6-[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonylcarbamoyl)piperidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C3OCCOC3=CC=2)CC1 KIPUPHQPSGWIFX-UHFFFAOYSA-N 0.000 claims description 2
- SXBLWMMNQDYGTG-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(2-methylphenyl)sulfonylcarbamoyl]piperazin-1-yl]-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)CC1 SXBLWMMNQDYGTG-UHFFFAOYSA-N 0.000 claims description 2
- USFSMRAJQUFCNV-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(4-fluorophenyl)sulfonylcarbamoyl]piperazin-1-yl]-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(F)=CC=2)CC1 USFSMRAJQUFCNV-UHFFFAOYSA-N 0.000 claims description 2
- HWIBBJSFZYEVKI-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(4-methylphenyl)sulfonylcarbamoyl]piperazin-1-yl]-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)CC1 HWIBBJSFZYEVKI-UHFFFAOYSA-N 0.000 claims description 2
- AINYGOJLEKAPSB-UHFFFAOYSA-N ethyl 6-[3-(1-benzothiophen-3-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=CC=CC=C3SC=2)C1 AINYGOJLEKAPSB-UHFFFAOYSA-N 0.000 claims description 2
- QMUBZDPIKPJIAM-UHFFFAOYSA-N ethyl 6-[3-[(2-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)C1 QMUBZDPIKPJIAM-UHFFFAOYSA-N 0.000 claims description 2
- YTYTVBHMGSRCRN-UHFFFAOYSA-N ethyl 6-[3-[(3-bromo-5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C=C(Cl)S2)Br)C1 YTYTVBHMGSRCRN-UHFFFAOYSA-N 0.000 claims description 2
- BPLBHGMLIYZDHX-UHFFFAOYSA-N ethyl 6-[3-[(3-bromophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Br)C=CC=2)C1 BPLBHGMLIYZDHX-UHFFFAOYSA-N 0.000 claims description 2
- XJAUTURGAVKIGW-UHFFFAOYSA-N ethyl 6-[3-[(4-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)C1 XJAUTURGAVKIGW-UHFFFAOYSA-N 0.000 claims description 2
- XTRNTMPKWKEDFN-UHFFFAOYSA-N ethyl 6-[3-[(5-bromo-6-chloropyridin-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Br)C(Cl)=NC=2)C1 XTRNTMPKWKEDFN-UHFFFAOYSA-N 0.000 claims description 2
- VKIAIPSYXFDGAT-UHFFFAOYSA-N ethyl 6-[3-[(5-bromothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Br)=CC=2)C1 VKIAIPSYXFDGAT-UHFFFAOYSA-N 0.000 claims description 2
- CILSRBUAKHLULT-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Cl)SC=2)C1 CILSRBUAKHLULT-UHFFFAOYSA-N 0.000 claims description 2
- OEHPMXIXGIETEF-UHFFFAOYSA-N ethyl 6-[3-[2-(benzenesulfonamido)-2-oxoethyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 OEHPMXIXGIETEF-UHFFFAOYSA-N 0.000 claims description 2
- BTIAERCPSGMCCD-UHFFFAOYSA-N ethyl 6-[3-[2-(benzenesulfonamido)-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2C=CC=CC=2)CCC1 BTIAERCPSGMCCD-UHFFFAOYSA-N 0.000 claims description 2
- PXFRQBZGPSLQEF-UHFFFAOYSA-N ethyl 6-[3-[2-[(5-chlorothiophen-2-yl)sulfonylamino]-2-oxoethyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 PXFRQBZGPSLQEF-UHFFFAOYSA-N 0.000 claims description 2
- LBVFFPZDCSCYIN-UHFFFAOYSA-N ethyl 6-[3-[2-[(5-chlorothiophen-2-yl)sulfonylamino]-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CCC1 LBVFFPZDCSCYIN-UHFFFAOYSA-N 0.000 claims description 2
- HZWVJSZPVJHIRF-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 HZWVJSZPVJHIRF-UHFFFAOYSA-N 0.000 claims description 2
- CSJGQSBCSQFHSP-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-2-methylpiperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1C(C)CN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CSJGQSBCSQFHSP-UHFFFAOYSA-N 0.000 claims description 2
- FLCWYHVLJNVKMZ-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-3-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(Cl)SC=2)CC1 FLCWYHVLJNVKMZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- NPPOKWMMVGLMKT-UHFFFAOYSA-N methyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 NPPOKWMMVGLMKT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- FBKFIXSPHXLDBO-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-(dimethylamino)-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1N(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 FBKFIXSPHXLDBO-UHFFFAOYSA-N 0.000 claims description 2
- DQLKCWKKVZXRJB-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]azetidine-3-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CC(C2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C DQLKCWKKVZXRJB-UHFFFAOYSA-N 0.000 claims description 2
- QASBJHOKEXMTDM-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[5-(5-ethyl-1,3-oxazol-2-yl)-3-(methylamino)pyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1NC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 QASBJHOKEXMTDM-UHFFFAOYSA-N 0.000 claims description 2
- GBUMWIGVMHGMCP-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[5-(5-ethyl-1,3-oxazol-2-yl)-3-(propan-2-ylamino)pyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1NC(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 GBUMWIGVMHGMCP-UHFFFAOYSA-N 0.000 claims description 2
- SVYOVAPCHNLQFI-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[5-(5-ethyl-1,3-oxazol-2-yl)-3-methylpyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 SVYOVAPCHNLQFI-UHFFFAOYSA-N 0.000 claims description 2
- GMHMCXJIVCUHHK-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-methyl-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 GMHMCXJIVCUHHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 2
- BNWSSSRHCIQYBY-UHFFFAOYSA-N propan-2-yl 5-cyano-2-methyl-6-[3-(naphthalen-2-ylsulfonylcarbamoyl)azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C1 BNWSSSRHCIQYBY-UHFFFAOYSA-N 0.000 claims description 2
- KBNWMZBWSPYZLF-UHFFFAOYSA-N propan-2-yl 5-cyano-2-methyl-6-[3-[[4-(trifluoromethyl)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)C1 KBNWMZBWSPYZLF-UHFFFAOYSA-N 0.000 claims description 2
- VPKGLJUFALVDAM-UHFFFAOYSA-N propan-2-yl 5-cyano-2-methyl-6-[4-[(5-methylthiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(C)=CC=2)CC1 VPKGLJUFALVDAM-UHFFFAOYSA-N 0.000 claims description 2
- FENUGUXRROVJPM-UHFFFAOYSA-N propan-2-yl 5-cyano-6-[4-[(4-methoxyphenyl)sulfonylcarbamoyl]piperidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC(=O)C1CCN(C=2C(=CC(=C(C)N=2)C(=O)OC(C)C)C#N)CC1 FENUGUXRROVJPM-UHFFFAOYSA-N 0.000 claims description 2
- LCEALTZDXMMLFT-UHFFFAOYSA-N propan-2-yl 6-[4-[(4-chlorophenyl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 LCEALTZDXMMLFT-UHFFFAOYSA-N 0.000 claims description 2
- XISVCAGCODBBBH-UHFFFAOYSA-N propyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XISVCAGCODBBBH-UHFFFAOYSA-N 0.000 claims description 2
- RUFQLCKFXFDRFY-UHFFFAOYSA-N tert-butyl 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OC(C)(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RUFQLCKFXFDRFY-UHFFFAOYSA-N 0.000 claims description 2
- JTNZXLLKKARAHG-UHFFFAOYSA-N tert-butyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C1=C(C(=O)OC(C)(C)C)C(C)=NC(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)=C1C#N JTNZXLLKKARAHG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- NHNYOXVQBWSJQQ-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-3-[1-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]azetidin-3-yl]urea Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CC(C2)NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C NHNYOXVQBWSJQQ-UHFFFAOYSA-N 0.000 claims 1
- VCMOVXCUSZCATA-UHFFFAOYSA-N 1-[1-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]azetidin-3-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CC(C2)NC(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)N=C1C VCMOVXCUSZCATA-UHFFFAOYSA-N 0.000 claims 1
- YXGKOLAZDGNTBX-UHFFFAOYSA-N 1-[3-chloro-4-(dimethylamino)-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)N(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 YXGKOLAZDGNTBX-UHFFFAOYSA-N 0.000 claims 1
- KTGUJCHPSDTAKP-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-(methylamino)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)NC)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 KTGUJCHPSDTAKP-UHFFFAOYSA-N 0.000 claims 1
- XUIXLOZKWFTJCA-UHFFFAOYSA-N 1-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)-4-methylpyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XUIXLOZKWFTJCA-UHFFFAOYSA-N 0.000 claims 1
- QEZAVXUBUOSDEI-UHFFFAOYSA-N 1-[3-chloro-5-(5-propyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CCC)=CN=C1C(C=C1Cl)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 QEZAVXUBUOSDEI-UHFFFAOYSA-N 0.000 claims 1
- RNEYONGXTVFBHV-UHFFFAOYSA-N 1-[4-amino-3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C(=C1Cl)N)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RNEYONGXTVFBHV-UHFFFAOYSA-N 0.000 claims 1
- INYUXDNBIIOJJT-UHFFFAOYSA-N 2,2-dimethylpropyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C1=C(C(=O)OCC(C)(C)C)C(C)=NC(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)=C1C#N INYUXDNBIIOJJT-UHFFFAOYSA-N 0.000 claims 1
- WARBCCJQZNEMOP-UHFFFAOYSA-N 4-[3-chloro-5-(5-ethyl-1,2,4-oxadiazol-3-yl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(CC)=NC(C=2C=C(Cl)C(N3CCN(CC3)C(=O)NS(=O)(=O)C=3SC(Cl)=CC=3)=NC=2)=N1 WARBCCJQZNEMOP-UHFFFAOYSA-N 0.000 claims 1
- VEJNOPYLXFLQPA-UHFFFAOYSA-N 4-[3-chloro-5-(cyclopropanecarbonyl)pyridin-2-yl]-n-(5-chlorothiophen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)NC(=O)N1CCN(C=2C(=CC(=CN=2)C(=O)C2CC2)Cl)CC1 VEJNOPYLXFLQPA-UHFFFAOYSA-N 0.000 claims 1
- NSNYUHLSOAUSPF-UHFFFAOYSA-N ethyl 5-chloro-6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 NSNYUHLSOAUSPF-UHFFFAOYSA-N 0.000 claims 1
- LWUMYRAPPSSZQT-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(4-fluorophenyl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC(F)=CC=2)CC1 LWUMYRAPPSSZQT-UHFFFAOYSA-N 0.000 claims 1
- UCPWBOJNWFWDJU-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-(naphthalen-2-ylsulfonylcarbamoyl)azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C1 UCPWBOJNWFWDJU-UHFFFAOYSA-N 0.000 claims 1
- WZKREEXHYUVNMZ-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-(pyridin-3-ylsulfonylcarbamoyl)azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=NC=CC=2)C1 WZKREEXHYUVNMZ-UHFFFAOYSA-N 0.000 claims 1
- ZZVDGZDWHSORFX-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-(thiophen-2-ylsulfonylcarbamoyl)azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC=CC=2)C1 ZZVDGZDWHSORFX-UHFFFAOYSA-N 0.000 claims 1
- MWXLHSIKTZWNJT-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-(thiophen-3-ylsulfonylcarbamoyl)azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=CSC=C2)C1 MWXLHSIKTZWNJT-UHFFFAOYSA-N 0.000 claims 1
- SDKIGEKJXKDSDF-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(2-methyl-5-methylsulfonylphenyl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC=C(C=2)S(C)(=O)=O)C)C1 SDKIGEKJXKDSDF-UHFFFAOYSA-N 0.000 claims 1
- ZHFHXPJWZRILQW-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(3-methylphenyl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(C)C=CC=2)C1 ZHFHXPJWZRILQW-UHFFFAOYSA-N 0.000 claims 1
- VHNAEMUQCNDUCA-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(3-nitrophenyl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)C1 VHNAEMUQCNDUCA-UHFFFAOYSA-N 0.000 claims 1
- IXSCILHZBWHKMP-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(4-methylphenyl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)C1 IXSCILHZBWHKMP-UHFFFAOYSA-N 0.000 claims 1
- DSWXVCARDLNTIT-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[(5-pyridin-2-ylthiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)C1 DSWXVCARDLNTIT-UHFFFAOYSA-N 0.000 claims 1
- DCDQBKBFCNYYMS-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[2-(trifluoromethoxy)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)OC(F)(F)F)C1 DCDQBKBFCNYYMS-UHFFFAOYSA-N 0.000 claims 1
- YXXXGIVQMQMLIM-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[3-(3-methyl-5-oxo-4h-pyrazol-1-yl)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)N2C(CC(C)=N2)=O)C1 YXXXGIVQMQMLIM-UHFFFAOYSA-N 0.000 claims 1
- YYFNVPMTPVWPID-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[4-(2h-tetrazol-5-yl)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(=CC=2)C=2NN=NN=2)C1 YYFNVPMTPVWPID-UHFFFAOYSA-N 0.000 claims 1
- MBBVGRUBPSYLDG-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[4-(trifluoromethoxy)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)C1 MBBVGRUBPSYLDG-UHFFFAOYSA-N 0.000 claims 1
- ONBZGRYQPYCFEZ-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[4-(trifluoromethyl)phenyl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)C1 ONBZGRYQPYCFEZ-UHFFFAOYSA-N 0.000 claims 1
- HDTSQPHQWYPJHN-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[5-(1,2-oxazol-3-yl)thiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C2=NOC=C2)C1 HDTSQPHQWYPJHN-UHFFFAOYSA-N 0.000 claims 1
- TUEKMSMEFFRCRK-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[5-(1,2-oxazol-5-yl)thiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C=2ON=CC=2)C1 TUEKMSMEFFRCRK-UHFFFAOYSA-N 0.000 claims 1
- DSAJEXXRLNYMDQ-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[5-(2-methyl-1,3-thiazol-4-yl)thiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C=2N=C(C)SC=2)C1 DSAJEXXRLNYMDQ-UHFFFAOYSA-N 0.000 claims 1
- JNMBDRMMBLKLIT-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[[5-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(=CC=2)C2=NN(C)C(=C2)C(F)(F)F)C1 JNMBDRMMBLKLIT-UHFFFAOYSA-N 0.000 claims 1
- SVTIGMRPWSAVLC-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[3-[methyl-(4-methylphenyl)sulfonylcarbamoyl]azetidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)N(C)S(=O)(=O)C=2C=CC(C)=CC=2)C1 SVTIGMRPWSAVLC-UHFFFAOYSA-N 0.000 claims 1
- CDQSDJQNKAAAKL-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[4-(naphthalen-2-ylsulfonylcarbamoyl)piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 CDQSDJQNKAAAKL-UHFFFAOYSA-N 0.000 claims 1
- ZPHHTRXBWHYRNQ-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[4-[(3-nitrophenyl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)CC1 ZPHHTRXBWHYRNQ-UHFFFAOYSA-N 0.000 claims 1
- OPRGCVLMAIMTQV-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[4-[(4-methylphenyl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)CC1 OPRGCVLMAIMTQV-UHFFFAOYSA-N 0.000 claims 1
- WPYNRWOZLHPBJY-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[4-[[2-(trifluoromethoxy)phenyl]sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)OC(F)(F)F)CC1 WPYNRWOZLHPBJY-UHFFFAOYSA-N 0.000 claims 1
- UUDAQXYCZGSXIT-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-[4-[[4-(trifluoromethoxy)phenyl]sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)CC1 UUDAQXYCZGSXIT-UHFFFAOYSA-N 0.000 claims 1
- DRORMAQDFUUTRR-UHFFFAOYSA-N ethyl 5-cyano-6-[3-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonylcarbamoyl)azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C3OCCOC3=CC=2)C1 DRORMAQDFUUTRR-UHFFFAOYSA-N 0.000 claims 1
- CMHTWGGAVQSKAL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(N=C(C)S2)C)C1 CMHTWGGAVQSKAL-UHFFFAOYSA-N 0.000 claims 1
- BGXQTUVWYLQULN-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dichlorothiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(SC(Cl)=C2)Cl)C1 BGXQTUVWYLQULN-UHFFFAOYSA-N 0.000 claims 1
- UTEGZDGSGWVSOL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2,5-dimethylthiophen-3-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(SC(C)=C2)C)C1 UTEGZDGSGWVSOL-UHFFFAOYSA-N 0.000 claims 1
- WOSXZOGZKZBVKT-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(2-fluorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)F)C1 WOSXZOGZKZBVKT-UHFFFAOYSA-N 0.000 claims 1
- YUHYWCSQMSABOS-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3,4-dichlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)C1 YUHYWCSQMSABOS-UHFFFAOYSA-N 0.000 claims 1
- MHPMVBQMVHYRKR-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3,4-dimethoxyphenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(OC)C(OC)=CC=2)C1 MHPMVBQMVHYRKR-UHFFFAOYSA-N 0.000 claims 1
- SYBXYCVFCLIGRZ-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3,5-difluorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(F)C=C(F)C=2)C1 SYBXYCVFCLIGRZ-UHFFFAOYSA-N 0.000 claims 1
- DVYAJWIFDCCWGA-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3-cyanophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)C#N)C1 DVYAJWIFDCCWGA-UHFFFAOYSA-N 0.000 claims 1
- YFYRPFWOJLHUNU-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3-fluorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(F)C=CC=2)C1 YFYRPFWOJLHUNU-UHFFFAOYSA-N 0.000 claims 1
- LNKAIDPJTVDPDQ-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(3-methoxyphenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(OC)C=CC=2)C1 LNKAIDPJTVDPDQ-UHFFFAOYSA-N 0.000 claims 1
- JATGFNWHQMGBMT-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4-fluorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC(F)=CC=2)C1 JATGFNWHQMGBMT-UHFFFAOYSA-N 0.000 claims 1
- KVPUDJVNYHWGRL-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(4-methoxycarbonyl-5-methylfuran-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2OC(C)=C(C(=O)OC)C=2)C1 KVPUDJVNYHWGRL-UHFFFAOYSA-N 0.000 claims 1
- TYMAWUNFRZHRGA-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(5-methoxycarbonylfuran-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2OC(=CC=2)C(=O)OC)C1 TYMAWUNFRZHRGA-UHFFFAOYSA-N 0.000 claims 1
- NJFDXLVTTSQPFC-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC3=CC(OCC)=CC=C3N=2)C1 NJFDXLVTTSQPFC-UHFFFAOYSA-N 0.000 claims 1
- HTZUPOGLTWFCFA-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(2,4-dichlorophenyl)sulfonylcarbamoyl]piperidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C(=CC(Cl)=CC=2)Cl)CC1 HTZUPOGLTWFCFA-UHFFFAOYSA-N 0.000 claims 1
- YNURQPMKLAELQO-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(3-cyanophenyl)sulfonylcarbamoyl]piperidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(C=CC=2)C#N)CC1 YNURQPMKLAELQO-UHFFFAOYSA-N 0.000 claims 1
- PZRCOTDQTBAWDO-UHFFFAOYSA-N ethyl 5-cyano-6-[4-[(4-methoxyphenyl)sulfonylcarbamoyl]piperidin-1-yl]-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC(OC)=CC=2)CC1 PZRCOTDQTBAWDO-UHFFFAOYSA-N 0.000 claims 1
- ZVMFZNZLUQHWAV-KBPBESRZSA-N ethyl 6-[(1s,4s)-2-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-2,5-diazabicyclo[2.2.1]heptan-5-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)NS(=O)(=O)C=1SC(Cl)=CC=1)[H])N2C1=NC(C)=C(C(=O)OCC)C=C1C#N ZVMFZNZLUQHWAV-KBPBESRZSA-N 0.000 claims 1
- WJILKOXJPCLHAH-UHFFFAOYSA-N ethyl 6-[3-(2,1,3-benzothiadiazol-4-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=NSN=C3C=CC=2)C1 WJILKOXJPCLHAH-UHFFFAOYSA-N 0.000 claims 1
- RSGPBIDJRJPCAV-UHFFFAOYSA-N ethyl 6-[3-(2,1,3-benzoxadiazol-4-ylsulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C3=NON=C3C=CC=2)C1 RSGPBIDJRJPCAV-UHFFFAOYSA-N 0.000 claims 1
- ZOTDNPNVLACERX-UHFFFAOYSA-N ethyl 6-[3-(benzenesulfonylcarbamoyl)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 ZOTDNPNVLACERX-UHFFFAOYSA-N 0.000 claims 1
- LROWHZKBLPBFIX-UHFFFAOYSA-N ethyl 6-[3-(benzenesulfonylcarbamoylamino)azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(NC(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 LROWHZKBLPBFIX-UHFFFAOYSA-N 0.000 claims 1
- UKLTWOHKSDYECL-UHFFFAOYSA-N ethyl 6-[3-[(3-chlorophenyl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2C=C(Cl)C=CC=2)C1 UKLTWOHKSDYECL-UHFFFAOYSA-N 0.000 claims 1
- PNUQKPNRDARCJX-UHFFFAOYSA-N ethyl 6-[3-[(4-bromo-5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=C(Br)C=2)C1 PNUQKPNRDARCJX-UHFFFAOYSA-N 0.000 claims 1
- SFEMQHGKMZJZDT-UHFFFAOYSA-N ethyl 6-[3-[(4-chlorophenyl)sulfonylcarbamoylamino]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(NC(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)C1 SFEMQHGKMZJZDT-UHFFFAOYSA-N 0.000 claims 1
- MFBHEUSXFARQEY-UHFFFAOYSA-N ethyl 6-[3-[(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(N(C)N=C2C)Cl)C1 MFBHEUSXFARQEY-UHFFFAOYSA-N 0.000 claims 1
- NLKBKVGXCVMBPS-UHFFFAOYSA-N ethyl 6-[3-[(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)C1 NLKBKVGXCVMBPS-UHFFFAOYSA-N 0.000 claims 1
- IQELNXOCRWDSJQ-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-3-methylazetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C)(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 IQELNXOCRWDSJQ-UHFFFAOYSA-N 0.000 claims 1
- VUULCTWERJCIOD-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 VUULCTWERJCIOD-UHFFFAOYSA-N 0.000 claims 1
- DXRGSOKOVRDWNW-UHFFFAOYSA-N ethyl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 DXRGSOKOVRDWNW-UHFFFAOYSA-N 0.000 claims 1
- WSZQGNXHCKRDDX-UHFFFAOYSA-N ethyl 6-[3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C=2N3C=CSC3=NC=2Cl)C1 WSZQGNXHCKRDDX-UHFFFAOYSA-N 0.000 claims 1
- GPRURVBIOGGQIW-UHFFFAOYSA-N ethyl 6-[3-[(benzenesulfonylcarbamoylamino)methyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CNC(=O)NS(=O)(=O)C=2C=CC=CC=2)C1 GPRURVBIOGGQIW-UHFFFAOYSA-N 0.000 claims 1
- OLFOOGHYEKTXRY-UHFFFAOYSA-N ethyl 6-[3-[[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]methyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(CNC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 OLFOOGHYEKTXRY-UHFFFAOYSA-N 0.000 claims 1
- FWXUMSNWEZCCIT-UHFFFAOYSA-N ethyl 6-[3-[[4-(4-chlorophenyl)sulfonyl-3-methylthiophen-2-yl]sulfonylcarbamoyl]azetidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(=O)NS(=O)(=O)C2=C(C(=CS2)S(=O)(=O)C=2C=CC(Cl)=CC=2)C)C1 FWXUMSNWEZCCIT-UHFFFAOYSA-N 0.000 claims 1
- MSQMWODDPRBPJG-UHFFFAOYSA-N ethyl 6-[4-(2,1,3-benzoxadiazol-4-ylsulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C3=NON=C3C=CC=2)CC1 MSQMWODDPRBPJG-UHFFFAOYSA-N 0.000 claims 1
- SLFSAOTXKZLYMH-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-1,4-diazepan-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CCC1 SLFSAOTXKZLYMH-UHFFFAOYSA-N 0.000 claims 1
- XAQZFANMDXCKCF-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(=O)OC(C)(C)C)N(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 XAQZFANMDXCKCF-UHFFFAOYSA-N 0.000 claims 1
- PHZXEFQHQGATEP-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperazin-1-yl]-5-chloropyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 PHZXEFQHQGATEP-UHFFFAOYSA-N 0.000 claims 1
- HMUNNLCVCTTYGM-UHFFFAOYSA-N ethyl 6-[4-(benzenesulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 HMUNNLCVCTTYGM-UHFFFAOYSA-N 0.000 claims 1
- KVFVNZJNEHTWDB-UHFFFAOYSA-N ethyl 6-[4-[(4-chlorophenyl)sulfonylcarbamoylamino]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(NC(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 KVFVNZJNEHTWDB-UHFFFAOYSA-N 0.000 claims 1
- WXFHJUTYLPESPH-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-1,4-diazepan-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CCC1 WXFHJUTYLPESPH-UHFFFAOYSA-N 0.000 claims 1
- RGQQNQKBNSJCLB-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]-4-methylpiperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C)(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 RGQQNQKBNSJCLB-UHFFFAOYSA-N 0.000 claims 1
- CMEULPCPRSODMC-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-2,4-dimethylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=C(C)C=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 CMEULPCPRSODMC-UHFFFAOYSA-N 0.000 claims 1
- YVEPQWPFZNTAAE-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 YVEPQWPFZNTAAE-UHFFFAOYSA-N 0.000 claims 1
- PCCHEJANPILTFZ-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-phenylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C1=CC=CC=C1 PCCHEJANPILTFZ-UHFFFAOYSA-N 0.000 claims 1
- XPUHLVFTFLMVKI-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-propan-2-ylpyridine-3-carboxylate Chemical compound N1=C(C(C)C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 XPUHLVFTFLMVKI-UHFFFAOYSA-N 0.000 claims 1
- GFVMYYVRTZJDHI-UHFFFAOYSA-N ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoylamino]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(NC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 GFVMYYVRTZJDHI-UHFFFAOYSA-N 0.000 claims 1
- NWSAQANIQYQTHL-UHFFFAOYSA-N ethyl 6-[4-[2-(benzenesulfonamido)-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(CC(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 NWSAQANIQYQTHL-UHFFFAOYSA-N 0.000 claims 1
- ORDYIRKFBRMZAQ-UHFFFAOYSA-N ethyl 6-[4-[2-[(5-chlorothiophen-2-yl)sulfonylamino]-2-oxoethyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(CC(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 ORDYIRKFBRMZAQ-UHFFFAOYSA-N 0.000 claims 1
- XBBLJGOBAWABOE-UHFFFAOYSA-N ethyl 6-[5-(benzenesulfonylcarbamoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC2CN(C(=O)NS(=O)(=O)C=3C=CC=CC=3)CC2C1 XBBLJGOBAWABOE-UHFFFAOYSA-N 0.000 claims 1
- GFVRGXBBESESRL-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-(2,2-dimethylpropanoylamino)-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1NC(=O)C(C)(C)C)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 GFVRGXBBESESRL-UHFFFAOYSA-N 0.000 claims 1
- ALMLISXWGBQUKI-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CCC(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C ALMLISXWGBQUKI-UHFFFAOYSA-N 0.000 claims 1
- GDPUTNBZAXJXPV-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[3-cyano-5-(cyclopropanecarbonyl)-6-methylpyridin-2-yl]piperidine-4-carboxamide Chemical compound N#CC=1C=C(C(=O)C2CC2)C(C)=NC=1N(CC1)CCC1C(=O)NS(=O)(=O)C1=CC=C(Cl)S1 GDPUTNBZAXJXPV-UHFFFAOYSA-N 0.000 claims 1
- QXWFPNSWNSIFHP-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-1-[5-(5-ethyl-1,3-oxazol-2-yl)-3-nitropyridin-2-yl]piperidine-4-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1[N+]([O-])=O)=CN=C1N1CCC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 QXWFPNSWNSIFHP-UHFFFAOYSA-N 0.000 claims 1
- RXRZDIPEAWGXEI-UHFFFAOYSA-N n-(5-chlorothiophen-2-yl)sulfonyl-4-[3-cyano-5-(5-ethyl-1,3-oxazol-2-yl)-6-methylpyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(CC)=CN=C1C1=CC(C#N)=C(N2CCN(CC2)C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)N=C1C RXRZDIPEAWGXEI-UHFFFAOYSA-N 0.000 claims 1
- OKVOIJXNIGRZNY-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[3-chloro-5-(5-ethyl-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxamide Chemical compound O1C(CC)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 OKVOIJXNIGRZNY-UHFFFAOYSA-N 0.000 claims 1
- XQQSXVIULIYRIJ-UHFFFAOYSA-N propan-2-yl 5-cyano-2-methyl-6-[4-[(4-methylphenyl)sulfonylcarbamoyl]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC(C)=CC=2)CC1 XQQSXVIULIYRIJ-UHFFFAOYSA-N 0.000 claims 1
- NAVRLPPYEYKSHS-UHFFFAOYSA-N propan-2-yl 6-[3-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]azetidin-1-yl]-5-ethynyl-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#C)=C1N1CC(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)C1 NAVRLPPYEYKSHS-UHFFFAOYSA-N 0.000 claims 1
- XTDMWHYNGVIWJB-UHFFFAOYSA-N propan-2-yl 6-[4-(benzenesulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 XTDMWHYNGVIWJB-UHFFFAOYSA-N 0.000 claims 1
- ZHPWBXDMTDFJAT-UHFFFAOYSA-N propan-2-yl 6-[4-[(3-bromophenyl)sulfonylcarbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OC(C)C)=CC(C#N)=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(Br)C=CC=2)CC1 ZHPWBXDMTDFJAT-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000002172 P2Y12 inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 188
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 180
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 105
- 239000011541 reaction mixture Substances 0.000 description 97
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 96
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 95
- 235000019439 ethyl acetate Nutrition 0.000 description 88
- 238000006243 chemical reaction Methods 0.000 description 86
- 230000002829 reductive effect Effects 0.000 description 81
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 74
- 239000000460 chlorine Substances 0.000 description 65
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 58
- 239000002904 solvent Substances 0.000 description 53
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 52
- 229960001238 methylnicotinate Drugs 0.000 description 44
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 41
- 238000003818 flash chromatography Methods 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 37
- 235000019341 magnesium sulphate Nutrition 0.000 description 37
- 210000001772 blood platelet Anatomy 0.000 description 36
- 239000012043 crude product Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 30
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 28
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 26
- 239000012267 brine Substances 0.000 description 26
- 229920006395 saturated elastomer Polymers 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000013058 crude material Substances 0.000 description 21
- 238000002953 preparative HPLC Methods 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 150000007530 organic bases Chemical class 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 14
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 13
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 13
- 238000004220 aggregation Methods 0.000 description 13
- 229940093499 ethyl acetate Drugs 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 239000005695 Ammonium acetate Substances 0.000 description 11
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 11
- 235000019257 ammonium acetate Nutrition 0.000 description 11
- 229940043376 ammonium acetate Drugs 0.000 description 11
- 229960005141 piperazine Drugs 0.000 description 11
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- RKLQLYBJAZBSEU-UHFFFAOYSA-N 5-chlorothiophene-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)S1 RKLQLYBJAZBSEU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- UJYAZVSPFMJCLW-UHFFFAOYSA-N n-(oxomethylidene)benzenesulfonamide Chemical compound O=C=NS(=O)(=O)C1=CC=CC=C1 UJYAZVSPFMJCLW-UHFFFAOYSA-N 0.000 description 9
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 9
- CXWQAPHDSYDHBR-UHFFFAOYSA-N piperidine-4-carboxamide Chemical compound NC(=O)C1CCNCC1.NC(=O)C1CCNCC1 CXWQAPHDSYDHBR-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 8
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 8
- 101150041968 CDC13 gene Proteins 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229940124530 sulfonamide Drugs 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000001828 Gelatine Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 230000001732 thrombotic effect Effects 0.000 description 7
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 6
- 230000010118 platelet activation Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910052705 radium Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 150000003456 sulfonamides Chemical class 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- RMYHASGQQXXFLB-UHFFFAOYSA-N bromo-chloro-(trifluoromethylsulfonyl)-lambda3-iodane Chemical compound FC(F)(F)S(=O)(=O)I(Cl)Br RMYHASGQQXXFLB-UHFFFAOYSA-N 0.000 description 5
- BJNAOUVCLVYZQJ-UHFFFAOYSA-N ethyl 5-cyano-6-piperazin-1-yl-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CCNCC1 BJNAOUVCLVYZQJ-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229910052701 rubidium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 4
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 4
- PELGWIYVXNGZSM-UHFFFAOYSA-N 2,2,2-trichloroethyl n-(5-chlorothiophen-2-yl)sulfonylcarbamate Chemical compound ClC1=CC=C(S(=O)(=O)NC(=O)OCC(Cl)(Cl)Cl)S1 PELGWIYVXNGZSM-UHFFFAOYSA-N 0.000 description 4
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical group C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 4
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 4
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229960003009 clopidogrel Drugs 0.000 description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- PRXDPGKIGFSZOJ-UHFFFAOYSA-N ethyl 6-piperazin-1-yl-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC=C1N1CCNCC1 PRXDPGKIGFSZOJ-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 3
- MBQJQXSVUBSJDO-UHFFFAOYSA-N 1-(3-chloro-5-ethoxycarbonylpyridin-2-yl)azetidine-3-carboxylic acid Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(C(O)=O)C1 MBQJQXSVUBSJDO-UHFFFAOYSA-N 0.000 description 3
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 3
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 3
- ZJDPGWOBUURKFT-UHFFFAOYSA-N 5-chloro-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridine-3-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=C(C(O)=O)C=C1Cl ZJDPGWOBUURKFT-UHFFFAOYSA-N 0.000 description 3
- GCXJXQLYQLNMSW-UHFFFAOYSA-N 5-chloro-n-(oxomethylidene)thiophene-2-sulfonamide Chemical compound ClC1=CC=C(S(=O)(=O)N=C=O)S1 GCXJXQLYQLNMSW-UHFFFAOYSA-N 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 3
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 3
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229910003827 NRaRb Inorganic materials 0.000 description 3
- 229960005552 PAC-1 Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- QIVGFFFDXDKKOO-UHFFFAOYSA-N ethyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCNCC1 QIVGFFFDXDKKOO-UHFFFAOYSA-N 0.000 description 3
- JVPPDDVZHDBIPB-UHFFFAOYSA-N ethyl 5-cyano-2-methyl-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCNCC1 JVPPDDVZHDBIPB-UHFFFAOYSA-N 0.000 description 3
- VHQALQHLEOAPHH-UHFFFAOYSA-N ethyl 5-cyano-6-[3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound N1=C(C(F)(F)F)C(C(=O)OCC)=CC(C#N)=C1N1CC(CCC(=O)OC(C)(C)C)NCC1 VHQALQHLEOAPHH-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000009454 functional inhibition Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- UPWSRNIUPVRUCC-UHFFFAOYSA-N 1-(3-chloro-5-ethoxycarbonylpyridin-2-yl)piperidine-4-carboxylic acid Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(C(O)=O)CC1 UPWSRNIUPVRUCC-UHFFFAOYSA-N 0.000 description 2
- PXLDGPHTWCKMDR-UHFFFAOYSA-N 1-(3-chloro-5-ethoxycarbonylpyridin-2-yl)pyrrolidine-3-carboxylic acid Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(C(O)=O)CC1 PXLDGPHTWCKMDR-UHFFFAOYSA-N 0.000 description 2
- QYQZQYJVCADJOA-UHFFFAOYSA-N 1-(5-chloro-6-piperazin-1-ylpyridin-3-yl)butan-1-one;dihydrochloride Chemical compound Cl.Cl.ClC1=CC(C(=O)CCC)=CN=C1N1CCNCC1 QYQZQYJVCADJOA-UHFFFAOYSA-N 0.000 description 2
- OYNNKOBQEKDLAA-UHFFFAOYSA-N 1-[3-chloro-5-(2-ethyltetrazol-5-yl)pyridin-2-yl]piperazine;dihydrochloride Chemical compound Cl.Cl.CCN1N=NC(C=2C=C(Cl)C(N3CCNCC3)=NC=2)=N1 OYNNKOBQEKDLAA-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- LALCDSDHLXWTTL-UHFFFAOYSA-N 2-chloro-n-(oxomethylidene)benzenesulfonamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)N=C=O LALCDSDHLXWTTL-UHFFFAOYSA-N 0.000 description 2
- HEBTZZBBPUFAFE-UHFFFAOYSA-N 2-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=CC=C1S(=O)(=O)N=C=O HEBTZZBBPUFAFE-UHFFFAOYSA-N 0.000 description 2
- BOLVZEJDGVWEQB-UHFFFAOYSA-N 3-methylbutyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCC(C)C)=CN=C1N1CCNCC1 BOLVZEJDGVWEQB-UHFFFAOYSA-N 0.000 description 2
- JGHDVROWMPBQSR-UHFFFAOYSA-N 4-chloro-n-(oxomethylidene)benzenesulfonamide Chemical compound ClC1=CC=C(S(=O)(=O)N=C=O)C=C1 JGHDVROWMPBQSR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- FHMRJRSOWRCSKA-UHFFFAOYSA-N 4-fluoro-n-(oxomethylidene)benzenesulfonamide Chemical compound FC1=CC=C(S(=O)(=O)N=C=O)C=C1 FHMRJRSOWRCSKA-UHFFFAOYSA-N 0.000 description 2
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010043647 Thrombotic Stroke Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000013176 antiplatelet therapy Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- JDEDNRPHTQXNDG-UHFFFAOYSA-N butyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCCC)=CN=C1N1CCNCC1 JDEDNRPHTQXNDG-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- JJBOZPGZEYEILU-UHFFFAOYSA-N methyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OC)=CN=C1N1CCNCC1 JJBOZPGZEYEILU-UHFFFAOYSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- WUNDTBKQEHFOEA-UHFFFAOYSA-N propyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCCC)=CN=C1N1CCNCC1 WUNDTBKQEHFOEA-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- BBAMWXWJUBFMOO-UHFFFAOYSA-N tert-butyl 4-[3-chloro-5-(2-hydroxypropylcarbamoyl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound ClC1=CC(C(=O)NCC(O)C)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 BBAMWXWJUBFMOO-UHFFFAOYSA-N 0.000 description 2
- 229940125670 thienopyridine Drugs 0.000 description 2
- 239000002175 thienopyridine Substances 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IFJADVKGZDVHID-UHFFFAOYSA-N 1-(3-cyano-5-ethoxycarbonyl-6-methylpyridin-2-yl)azetidine-3-carboxylic acid Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CC(C(O)=O)C1 IFJADVKGZDVHID-UHFFFAOYSA-N 0.000 description 1
- JPDCHUPRIIGKND-UHFFFAOYSA-N 1-(3-cyano-5-ethoxycarbonyl-6-methylpyridin-2-yl)piperidine-4-carboxylic acid Chemical compound N1=C(C)C(C(=O)OCC)=CC(C#N)=C1N1CCC(C(O)=O)CC1 JPDCHUPRIIGKND-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- BJVAENLIIOACPY-UHFFFAOYSA-N 1-benzothiophene-3-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CSC2=C1 BJVAENLIIOACPY-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- YSWWLKULIVOPEP-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-sulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=C2OCCC2=C1 YSWWLKULIVOPEP-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- BUQKISCVZMIFEF-UHFFFAOYSA-N 2,5-dichlorothiophene-3-sulfonamide Chemical compound NS(=O)(=O)C=1C=C(Cl)SC=1Cl BUQKISCVZMIFEF-UHFFFAOYSA-N 0.000 description 1
- SGKVBVKVYUQAGA-UHFFFAOYSA-N 2,5-dimethylfuran-3-sulfonamide Chemical compound CC1=CC(S(N)(=O)=O)=C(C)O1 SGKVBVKVYUQAGA-UHFFFAOYSA-N 0.000 description 1
- YKWISFQVVASOGF-UHFFFAOYSA-N 2,5-dimethylthiophene-3-sulfonamide Chemical compound CC1=CC(S(N)(=O)=O)=C(C)S1 YKWISFQVVASOGF-UHFFFAOYSA-N 0.000 description 1
- KZQREYNYKLBMGS-UHFFFAOYSA-N 2-(5-chloro-6-piperazin-1-ylpyridin-3-yl)-5-ethyl-4,5-dihydro-1,3-oxazole;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.O1C(CC)CN=C1C(C=C1Cl)=CN=C1N1CCNCC1 KZQREYNYKLBMGS-UHFFFAOYSA-N 0.000 description 1
- YAFYFJGTGGFTRB-UHFFFAOYSA-N 2-(5-chloro-6-piperazin-1-ylpyridin-3-yl)-5-methyl-1,3-oxazole;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCNCC1 YAFYFJGTGGFTRB-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-butanol Substances CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 1
- WFLBWYLZCQOPCA-UHFFFAOYSA-N 2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1F WFLBWYLZCQOPCA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ILLSOONBCBUBOD-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 ILLSOONBCBUBOD-UHFFFAOYSA-N 0.000 description 1
- MEZNPUULYGXXFL-UHFFFAOYSA-N 3,4-dimethoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1OC MEZNPUULYGXXFL-UHFFFAOYSA-N 0.000 description 1
- CRINBBOGNYCAOV-UHFFFAOYSA-N 3-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(F)=C1 CRINBBOGNYCAOV-UHFFFAOYSA-N 0.000 description 1
- VBKIEQKVSHDVGH-UHFFFAOYSA-N 3-methoxybenzenesulfonamide Chemical compound COC1=CC=CC(S(N)(=O)=O)=C1 VBKIEQKVSHDVGH-UHFFFAOYSA-N 0.000 description 1
- NVZINPVISUVPHW-UHFFFAOYSA-N 3-methylbenzenesulfonamide Chemical compound CC1=CC=CC(S(N)(=O)=O)=C1 NVZINPVISUVPHW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- TVHXQQJDMHKGGK-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 TVHXQQJDMHKGGK-UHFFFAOYSA-N 0.000 description 1
- HHHDJHHNEURCNV-UHFFFAOYSA-N 4-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1 HHHDJHHNEURCNV-UHFFFAOYSA-N 0.000 description 1
- LZMLUKAFBDCFMT-UHFFFAOYSA-N 5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide Chemical compound S1C(C)=NC(C=2SC(=CC=2)S(N)(=O)=O)=C1 LZMLUKAFBDCFMT-UHFFFAOYSA-N 0.000 description 1
- XAWYSMUSUNJJKM-UHFFFAOYSA-N 5-bromo-6-chloropyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=C(Cl)C(Br)=C1 XAWYSMUSUNJJKM-UHFFFAOYSA-N 0.000 description 1
- WXJQQLDICAOBJB-UHFFFAOYSA-N 5-bromothiophene-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)S1 WXJQQLDICAOBJB-UHFFFAOYSA-N 0.000 description 1
- PNISIGVJNFNPHB-UHFFFAOYSA-N 5-chloro-6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]pyridine-3-carboxylic acid Chemical compound ClC1=CC(C(=O)O)=CN=C1N1CCN(C(=O)NS(=O)(=O)C=2SC(Cl)=CC=2)CC1 PNISIGVJNFNPHB-UHFFFAOYSA-N 0.000 description 1
- JFPWDMDWNKWXMC-UHFFFAOYSA-N 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate;3-methylbutyl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate;piperazin-1-ium Chemical compound C1C[NH2+]CCN1.ClC1=CC(C(=O)[O-])=CN=C1N1CCNCC1.ClC1=CC(C(=O)OCCC(C)C)=CN=C1N1CCNCC1 JFPWDMDWNKWXMC-UHFFFAOYSA-N 0.000 description 1
- BUYHBTZQCXHXLJ-UHFFFAOYSA-N 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate;piperazin-1-ium Chemical compound C1C[NH2+]CCN1.ClC1=CC(C(=O)[O-])=CN=C1N1CCNCC1 BUYHBTZQCXHXLJ-UHFFFAOYSA-N 0.000 description 1
- PBJIEHRNSCJSPN-UHFFFAOYSA-N 5-chlorothiophene-3-sulfonamide Chemical compound NS(=O)(=O)C1=CSC(Cl)=C1 PBJIEHRNSCJSPN-UHFFFAOYSA-N 0.000 description 1
- SOMNHSWRZODVSQ-UHFFFAOYSA-N 5-cyano-2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=C(C#N)C=C1C(O)=O SOMNHSWRZODVSQ-UHFFFAOYSA-N 0.000 description 1
- QGYXQIUQBXAJCI-UHFFFAOYSA-N 5-methyl-1,2-oxazole-4-sulfonamide Chemical compound CC=1ON=CC=1S(N)(=O)=O QGYXQIUQBXAJCI-UHFFFAOYSA-N 0.000 description 1
- GBXCMGQOAFLRPE-UHFFFAOYSA-N 5-pyridin-2-ylthiophene-2-sulfonamide Chemical compound S1C(S(=O)(=O)N)=CC=C1C1=CC=CC=N1 GBXCMGQOAFLRPE-UHFFFAOYSA-N 0.000 description 1
- XTRZGKQIAJZWCF-UHFFFAOYSA-N 6-chloro-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(C#N)=C(Cl)N=C1C(F)(F)F XTRZGKQIAJZWCF-UHFFFAOYSA-N 0.000 description 1
- ZVRHRYRTZTWAHL-UHFFFAOYSA-N 6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide Chemical compound S1C=CN2C(S(=O)(=O)N)=C(Cl)N=C21 ZVRHRYRTZTWAHL-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical group [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 101100219283 Amycolatopsis orientalis cyp165C4 gene Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- CZSBYEUFUMHKRO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl.Cl.Cl.NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl Chemical compound C(C)(C)(C)OC(=O)NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl.Cl.Cl.NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl CZSBYEUFUMHKRO-UHFFFAOYSA-N 0.000 description 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VMEGVZYSFKAAGH-UHFFFAOYSA-N ClC=1C(=NC=C(C(=O)O)C1)Cl.ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1 Chemical compound ClC=1C(=NC=C(C(=O)O)C1)Cl.ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1 VMEGVZYSFKAAGH-UHFFFAOYSA-N 0.000 description 1
- RKALCXLIEOTINI-UHFFFAOYSA-N ClC=1C(=NC=C(C(=O)OCC)C1)Cl.C(C)(C)(C)OC(=O)NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl Chemical compound ClC=1C(=NC=C(C(=O)OCC)C1)Cl.C(C)(C)(C)OC(=O)NC1CN(C1)C1=NC=C(C(=O)OCC)C=C1Cl RKALCXLIEOTINI-UHFFFAOYSA-N 0.000 description 1
- RXLLIWMATMYRPU-UHFFFAOYSA-N ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1.ClC=1C(=NC=C(C(=O)OC)C1)N1CCNCC1 Chemical compound ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1.ClC=1C(=NC=C(C(=O)OC)C1)N1CCNCC1 RXLLIWMATMYRPU-UHFFFAOYSA-N 0.000 description 1
- ZYNSECKCCMOTIQ-UHFFFAOYSA-N ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1.ClC=1C(=NC=C(C(=O)OCCC)C1)N1CCNCC1 Chemical compound ClC=1C(=NC=C(C(=O)[O-])C1)N1CCNCC1.[NH2+]1CCNCC1.ClC=1C(=NC=C(C(=O)OCCC)C1)N1CCNCC1 ZYNSECKCCMOTIQ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 101000845005 Macrovipera lebetina Disintegrin lebein-2-alpha Proteins 0.000 description 1
- 229930190787 Mi-saponin Natural products 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241001435158 Nicetas Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910003870 O—Li Inorganic materials 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 229940127424 P2Y12 Receptor Antagonists Drugs 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040621 Shunt occlusion Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- SAFSAOMYNUEBBY-IOSLPCCCSA-N [(2r,3r,4r,5r)-5-(6-amino-2-methylpurin-9-yl)-3-hydroxy-4-sulfanyloxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1S SAFSAOMYNUEBBY-IOSLPCCCSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- LPVKRHSSXLLEJJ-UHFFFAOYSA-N di(imidazol-1-yl)methanone ethyl 6-[4-[(5-chlorothiophen-2-yl)sulfonylcarbamoyl]piperazin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate Chemical compound C(=O)(N1C=NC=C1)N1C=NC=C1.C(C)OC(C1=C(N=C(C(=C1)C#N)N1CCN(CC1)C(=O)NS(=O)(=O)C=1SC(=CC1)Cl)C)=O LPVKRHSSXLLEJJ-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- KBDKJZIOVWEQBQ-UHFFFAOYSA-N ethyl 5-chloro-6-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(NC(=O)OC(C)(C)C)C1 KBDKJZIOVWEQBQ-UHFFFAOYSA-N 0.000 description 1
- WZIWZTXGWVSIMR-UHFFFAOYSA-N ethyl 5-chloro-6-[3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CC(CCC(=O)OC(C)(C)C)NCC1 WZIWZTXGWVSIMR-UHFFFAOYSA-N 0.000 description 1
- DDRSUJJVYUSQJB-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]pyridine-3-carboxylate Chemical compound ClC1=CC(C(=O)OCC)=CN=C1N1CCC(NC(=O)OC(C)(C)C)CC1 DDRSUJJVYUSQJB-UHFFFAOYSA-N 0.000 description 1
- PYPDNLXERHWXSR-UHFFFAOYSA-N ethyl 5-chloro-6-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]pyridine-3-carboxylate;ethyl 5,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C(Cl)=C1.ClC1=CC(C(=O)OCC)=CN=C1N1CCC(NC(=O)OC(C)(C)C)CC1 PYPDNLXERHWXSR-UHFFFAOYSA-N 0.000 description 1
- PMDLSQHFIADYJD-UHFFFAOYSA-N ethyl 6-chloro-5-cyano-2-(trifluoromethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(Cl)N=C1C(F)(F)F PMDLSQHFIADYJD-UHFFFAOYSA-N 0.000 description 1
- QXZBVLFURRXJLB-UHFFFAOYSA-N ethyl 6-chloro-5-cyano-2-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(C#N)=C(Cl)N=C1C QXZBVLFURRXJLB-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- QTKAQJWFVXPIFV-YFKPBYRVSA-N methyl (2r)-2-acetamido-3-sulfanylpropanoate Chemical compound COC(=O)[C@H](CS)NC(C)=O QTKAQJWFVXPIFV-YFKPBYRVSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- CQUSHZSCDGSFBF-UHFFFAOYSA-N misaponine A Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(OC2C(C(O)C(OC3C(OCC(O)C3O)OC(=O)C34C(CC(C)(C)CC3)C=3C(C5(C)CC(O)C6C(C)(CO)C(OC7C(C(O)C(O)C(CO)O7)O)C(O)CC6(C)C5CC=3)(C)CC4)OC2C)O)OCC1O CQUSHZSCDGSFBF-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical class [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- MBOCAVOEIMDJNM-UHFFFAOYSA-N piperazine;1,2,3,4-tetrahydropyridazine;1,2,3,4-tetrahydropyrimidine Chemical compound C1CNCCN1.C1CC=CNN1.C1NCC=CN1 MBOCAVOEIMDJNM-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JIKQQDKFMZEMHC-UHFFFAOYSA-N propan-2-yl 5-chloro-6-piperazin-1-ylpyridine-3-carboxylate;dihydrochloride Chemical compound Cl.Cl.ClC1=CC(C(=O)OC(C)C)=CN=C1N1CCNCC1 JIKQQDKFMZEMHC-UHFFFAOYSA-N 0.000 description 1
- VSRSQDMWBSKNSF-UHFFFAOYSA-N propan-2-yl pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=CC=CN=C1 VSRSQDMWBSKNSF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- MFAWWKSDPGAERE-UHFFFAOYSA-N tert-butyl 3-piperazin-2-ylpropanoate Chemical compound CC(C)(C)OC(=O)CCC1CNCCN1 MFAWWKSDPGAERE-UHFFFAOYSA-N 0.000 description 1
- HXIBJAIIOGBVDS-UHFFFAOYSA-N tert-butyl 4-[3-chloro-5-(2-ethyltetrazol-5-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound CCN1N=NC(C=2C=C(Cl)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2)=N1 HXIBJAIIOGBVDS-UHFFFAOYSA-N 0.000 description 1
- RIUMSOZHBMZRGP-UHFFFAOYSA-N tert-butyl 4-[3-chloro-5-(2-hydroxybutylcarbamoyl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound ClC1=CC(C(=O)NCC(O)CC)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 RIUMSOZHBMZRGP-UHFFFAOYSA-N 0.000 description 1
- CXXUJGCYESPSAL-UHFFFAOYSA-N tert-butyl 4-[3-chloro-5-(2h-tetrazol-5-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=C(C2=NNN=N2)C=C1Cl CXXUJGCYESPSAL-UHFFFAOYSA-N 0.000 description 1
- VYWLNJOHBITPKT-UHFFFAOYSA-N tert-butyl 4-[3-chloro-5-(5-methyl-1,3-oxazol-2-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound O1C(C)=CN=C1C(C=C1Cl)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 VYWLNJOHBITPKT-UHFFFAOYSA-N 0.000 description 1
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000014754 thrombocytosis disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- VHKIEYIESYMHPT-UHFFFAOYSA-N triethyl(methoxycarbonylsulfamoyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)S(=O)(=O)NC(=O)OC VHKIEYIESYMHPT-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- BSRHWVYDTOKOQO-UHFFFAOYSA-N trifluoromethanesulfonyl iodide Chemical compound FC(F)(F)S(I)(=O)=O BSRHWVYDTOKOQO-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500140A GB0500140D0 (en) | 2005-01-06 | 2005-01-06 | Novel compounds |
| GB0500140.9 | 2005-01-06 | ||
| GB0521484A GB0521484D0 (en) | 2005-10-21 | 2005-10-21 | Novel compounds |
| GB0521484.6 | 2005-10-21 | ||
| PCT/SE2006/000010 WO2006073361A1 (en) | 2005-01-06 | 2006-01-04 | Novel pyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2594255A1 true CA2594255A1 (en) | 2006-07-13 |
Family
ID=36647772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002594255A Abandoned CA2594255A1 (en) | 2005-01-06 | 2006-01-04 | Novel pyridine compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090227555A2 (enExample) |
| EP (1) | EP1836189A1 (enExample) |
| JP (1) | JP2008526840A (enExample) |
| KR (1) | KR20070107024A (enExample) |
| AR (1) | AR055554A1 (enExample) |
| AU (1) | AU2006204159A1 (enExample) |
| BR (1) | BRPI0606437A (enExample) |
| CA (1) | CA2594255A1 (enExample) |
| IL (1) | IL183961A0 (enExample) |
| MX (1) | MX2007008237A (enExample) |
| NO (1) | NO20073101L (enExample) |
| RU (1) | RU2007129779A (enExample) |
| TW (1) | TW200626593A (enExample) |
| UY (1) | UY29325A1 (enExample) |
| WO (1) | WO2006073361A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312208A1 (en) * | 2005-07-13 | 2008-12-18 | Astrazeneca Ab | Pyridine Analogues |
| WO2008004941A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| WO2008004945A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline forms i and ii |
| TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
| WO2008004944A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline form ii |
| UY30867A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos analogos de piridina vii 543 |
| UY30868A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones. |
| UY30866A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolos y aplicaciones (519) |
| MX2009013431A (es) * | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| US20090018166A1 (en) * | 2007-07-13 | 2009-01-15 | Astrazeneca Ab | New Pyridine Analogues X 161 |
| WO2010005385A1 (en) * | 2008-07-07 | 2010-01-14 | Astrazeneca Ab | 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308 |
| WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP2014051434A (ja) * | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| SG11201500900YA (en) | 2012-08-21 | 2015-03-30 | Hoffmann La Roche | Novel pyridine derivatives |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| KR20240057402A (ko) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 그람 음성 박테리아 유출 펌프 억제제 |
| AU2023388768A1 (en) | 2022-12-06 | 2025-05-01 | Idorsia Pharmaceuticals Ltd | Crystalline adipic acid salt form of a ccr6 antagonist |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3133073B2 (ja) * | 1995-05-29 | 2001-02-05 | ファイザー・インコーポレーテッド | 成長ホルモンの放出を促進するジペプチド類 |
| EP1009405A4 (en) * | 1997-08-28 | 2001-05-09 | Merck & Co Inc | PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| FR2820057A1 (fr) * | 2001-01-30 | 2002-08-02 | Ct De Transfert De Technologie | Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane |
| WO2003022214A2 (en) * | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) * | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| WO2006012226A2 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| AU2007270083A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| WO2008004941A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New pyridine analogues |
| CN101511815A (zh) * | 2006-07-04 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 新型吡啶类似物 |
-
2006
- 2006-01-04 WO PCT/SE2006/000010 patent/WO2006073361A1/en not_active Ceased
- 2006-01-04 CA CA002594255A patent/CA2594255A1/en not_active Abandoned
- 2006-01-04 BR BRPI0606437-0A patent/BRPI0606437A/pt not_active IP Right Cessation
- 2006-01-04 MX MX2007008237A patent/MX2007008237A/es not_active Application Discontinuation
- 2006-01-04 JP JP2007550328A patent/JP2008526840A/ja active Pending
- 2006-01-04 AU AU2006204159A patent/AU2006204159A1/en not_active Abandoned
- 2006-01-04 EP EP06700210A patent/EP1836189A1/en not_active Withdrawn
- 2006-01-04 RU RU2007129779/04A patent/RU2007129779A/ru not_active Application Discontinuation
- 2006-01-04 US US11/813,289 patent/US20090227555A2/en not_active Abandoned
- 2006-01-04 KR KR1020077018077A patent/KR20070107024A/ko not_active Withdrawn
- 2006-01-05 UY UY29325A patent/UY29325A1/es unknown
- 2006-01-05 AR ARP060100040A patent/AR055554A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100677A patent/TW200626593A/zh unknown
-
2007
- 2007-06-14 IL IL183961A patent/IL183961A0/en unknown
- 2007-06-18 NO NO20073101A patent/NO20073101L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042852A1 (en) | 2009-02-12 |
| RU2007129779A (ru) | 2009-02-20 |
| AR055554A1 (es) | 2007-08-22 |
| JP2008526840A (ja) | 2008-07-24 |
| IL183961A0 (en) | 2007-10-31 |
| TW200626593A (en) | 2006-08-01 |
| MX2007008237A (es) | 2007-08-17 |
| BRPI0606437A (pt) | 2008-03-11 |
| UY29325A1 (es) | 2006-08-31 |
| NO20073101L (no) | 2007-07-19 |
| WO2006073361A9 (en) | 2007-08-02 |
| AU2006204159A1 (en) | 2006-07-13 |
| KR20070107024A (ko) | 2007-11-06 |
| EP1836189A1 (en) | 2007-09-26 |
| WO2006073361A1 (en) | 2006-07-13 |
| US20090227555A2 (en) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090186876A1 (en) | Pyridine Analogues II | |
| US20090042852A1 (en) | Novel Pyridine Compounds | |
| DE602004009089T2 (de) | Pyrrolderivate mit antibakterieller wirkung | |
| WO2008004942A1 (en) | New pyridine analogues | |
| AU2007270083A1 (en) | New pyridine analogues | |
| AU2007270081A1 (en) | New pyridine analogues | |
| WO2009011627A1 (en) | Pyridine compounds and their use as p2y12 antagonists | |
| AU2008203953A1 (en) | Pyridine compounds and their use as P2Y12 antagonists. | |
| US20080200448A1 (en) | New Pyridine Analogues VIII 518 | |
| CA2614726A1 (en) | New pyridine analogues | |
| WO2008085118A1 (en) | Pyridine compounds and their use as p2y12 antagonists. | |
| EP2044050A1 (en) | New pyridine analogues | |
| CN101137643A (zh) | 新型吡啶化合物 | |
| HK1124599A (en) | New pyridine analogues | |
| HK40048972A (en) | Inhibitors of cyclin-dependent kinases | |
| CN101479256A (zh) | 新的吡啶类似物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |